Celera's Proteomics Program Focuses on Biomarker-Based Lung Cancer Test

The company released results from studies of its six-protein diagnostic panel for lung cancer at this month's AACR meeting and this summer may take part in a 300-patient trial sponsored by the NCI's Early Detection Research Network.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.